Utility  	Utility  	 NN	O
of  	of  	 IN	O
bioimpedance  	bioimpedance  	 JJ	B-NP
spectroscopy  	spectroscopy  	 NNS	I-NP
( 	( 	 -LRB-	O
BIS 	BIS 	 NNP	B-NP
)  	)  	 -RRB-	O
in  	in  	 IN	O
the  	the  	 DT	O
management  	management  	 NN	O
of  	of  	 IN	O
refractory  	refractory  	 JJ	B-NP
hypertension  	hypertension  	 NN	I-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
chronic  	chronic  	 JJ	B-NP
kidney  	kidney  	 NN	I-NP
disease  	disease  	 NN	I-NP
( 	( 	 -LRB-	O
CKD 	CKD 	 NNP	B-NP
)  	)  	 -RRB-	O
Expansion  	Expansion  	 NN	O
of  	of  	 IN	O
extracellular  	extracellular  	 JJ	B-NP
volume  	volume  	 NN	I-NP
( 	( 	 -LRB-	O
ECV 	ECV 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
a  	a  	 DT	O
frequent  	frequent  	 JJ	O
cause  	cause  	 NN	O
of  	of  	 IN	O
resistant  	resistant  	 JJ	B-NP
hypertension  	hypertension  	 NN	I-NP
( 	( 	 -LRB-	O
RHT 	RHT 	 NNP	B-NP
)  	)  	 -RRB-	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
chronic  	chronic  	 JJ	B-NP
kidney  	kidney  	 NN	I-NP
disease  	disease  	 NN	I-NP
( 	( 	 -LRB-	O
CKD 	CKD 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
aim  	aim  	 NN	O
of  	of  	 IN	O
this  	this  	 DT	O
exploratory  	exploratory  	 JJ	B-NP
study  	study  	 NN	I-NP
was  	was  	 VBD	O
that  	that  	 IN	O
of  	of  	 IN	O
applying  	applying  	 VBG	O
bioimpedance  	bioimpedance  	 JJ	B-NP
spectroscopy  	spectroscopy  	 NNS	I-NP
( 	( 	 -LRB-	O
BIS 	BIS 	 NNP	B-NP
)  	)  	 -RRB-	O
for  	for  	 IN	O
the  	the  	 DT	O
identification  	identification  	 NN	B-NP
of  	of  	 IN	I-NP
CKD  	CKD  	 NNP	I-NP
patients  	patients  	 NNS	I-NP
with  	with  	 IN	O
RHT  	RHT  	 NNP	B-NP
and  	and  	 CC	O
expansion  	expansion  	 NN	O
of  	of  	 IN	O
ECV 	ECV 	 NNP	B-NP
,  	,  	 ,	O
while  	while  	 IN	O
trying  	trying  	 VBG	O
to  	to  	 TO	O
control  	control  	 VB	O
blood  	blood  	 NN	B-NP
pressure  	pressure  	 NN	I-NP
( 	( 	 -LRB-	O
BP 	BP 	 NNP	B-NP
)  	)  	 -RRB-	O
using  	using  	 VBG	O
an  	an  	 DT	O
intensification  	intensification  	 NN	B-NP
of  	of  	 IN	I-NP
diuretic  	diuretic  	 JJ	I-NP
treatment 	treatment 	 NN	I-NP
.  	.  	 .	O
We  	We  	 PRP	O
included  	included  	 VBD	O
50  	50  	 CD	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
RHT  	RHT  	 NNP	B-NP
and  	and  	 CC	O
CKD  	CKD  	 NNP	B-NP
who  	who  	 WP	O
underwent  	underwent  	 VBD	O
BIS 	BIS 	 NNP	B-NP
.  	.  	 .	O
In  	In  	 IN	O
order  	order  	 NN	O
to  	to  	 TO	O
control  	control  	 VB	O
BP 	BP 	 NNP	B-NP
,  	,  	 ,	O
diuretic  	diuretic  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
was  	was  	 VBD	O
intensified  	intensified  	 VBN	O
in  	in  	 IN	O
those  	those  	 DT	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
expansion  	expansion  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
ECV 	ECV 	 NNP	B-NP
.  	.  	 .	O
In  	In  	 IN	O
all  	all  	 DT	O
other  	other  	 JJ	O
cases 	cases 	 NNS	O
,  	,  	 ,	O
another  	another  	 DT	O
antihypertensive  	antihypertensive  	 JJ	B-NP
drug  	drug  	 NN	I-NP
was  	was  	 VBD	O
added 	added 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
mean  	mean  	 JJ	O
age  	age  	 NN	O
was  	was  	 VBD	O
68.2  	68.2  	 CD	O
±  	±  	 CD	O
10.4  	10.4  	 CD	O
years 	years 	 NNS	O
,  	,  	 ,	O
68 	68 	 CD	O
%  	%  	 NN	O
were  	were  	 VBD	O
male  	male  	 JJ	O
and  	and  	 CC	O
58 	58 	 CD	O
%  	%  	 NN	O
were  	were  	 VBD	O
diabetic 	diabetic 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
mean  	mean  	 VBP	O
estimated  	estimated  	 VBN	B-NP
glomerular  	glomerular  	 JJ	I-NP
filtration  	filtration  	 JJ	I-NP
rate  	rate  	 NN	I-NP
( 	( 	 -LRB-	O
eGFR 	eGFR 	 NNP	B-NP
)  	)  	 -RRB-	O
was  	was  	 VBD	O
50.7  	50.7  	 CD	O
±  	±  	 CD	O
22.4  	22.4  	 CD	O
mL 	mL 	 JJ	O
/ 	/ 	 FW	O
min 	min 	 FW	O
/ 	/ 	 FW	O
1.72  	1.72  	 FW	O
m 	m 	 FW	B-NP
( 	( 	 -LRB-	I-NP
2 	2 	 LS	I-NP
) 	) 	 -RRB-	I-NP
.  	.  	 .	O
Baseline  	Baseline  	 NNP	B-NP
systolic  	systolic  	 VBD	O
BP  	BP  	 NNP	B-NP
was  	was  	 VBD	O
167.2  	167.2  	 CD	O
±  	±  	 CD	O
8.6  	8.6  	 CD	O
mmHg  	mmHg  	 JJ	O
and  	and  	 CC	O
diastolic  	diastolic  	 JJ	B-NP
BP  	BP  	 NNP	I-NP
was  	was  	 VBD	O
84.8  	84.8  	 CD	O
±  	±  	 CD	O
9.5  	9.5  	 CD	O
mmHg 	mmHg 	 NN	B-NP
.  	.  	 .	O
The  	The  	 DT	O
mean  	mean  	 JJ	O
number  	number  	 NN	O
of  	of  	 IN	O
antihypertensive  	antihypertensive  	 JJ	B-NP
drugs  	drugs  	 NNS	I-NP
received  	received  	 VBD	O
was  	was  	 VBD	O
3.8  	3.8  	 CD	O
±  	±  	 CD	O
0.9 	0.9 	 CD	O
.  	.  	 .	O
Expansion  	Expansion  	 NN	O
of  	of  	 IN	O
ECV  	ECV  	 NNP	B-NP
was  	was  	 VBD	O
recorded  	recorded  	 VBN	O
in  	in  	 IN	O
30  	30  	 CD	O
( 	( 	 -LRB-	O
60 	60 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
patients  	patients  	 NNS	O
and  	and  	 CC	O
was  	was  	 VBD	O
more  	more  	 RBR	O
frequent  	frequent  	 JJ	O
in  	in  	 IN	O
diabetics  	diabetics  	 NNS	O
and  	and  	 CC	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
more  	more  	 JJR	O
albuminuria 	albuminuria 	 NN	B-NP
.  	.  	 .	O
At  	At  	 IN	O
6  	6  	 CD	O
months  	months  	 NNS	O
of  	of  	 IN	O
follow-up 	follow-up 	 NNP	O
,  	,  	 ,	O
a  	a  	 DT	O
decline  	decline  	 NN	O
of  	of  	 IN	O
21.4  	21.4  	 CD	O
±  	±  	 CD	O
7.1  	7.1  	 CD	O
mmHg  	mmHg  	 NN	B-NP
was  	was  	 VBD	O
observed  	observed  	 VBN	O
in  	in  	 IN	O
systolic  	systolic  	 JJ	B-NP
BP  	BP  	 NNP	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
expansion  	expansion  	 NN	O
of  	of  	 IN	O
ECV 	ECV 	 NNP	B-NP
,  	,  	 ,	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
a  	a  	 DT	O
decrease  	decrease  	 NN	O
of  	of  	 IN	O
9.4  	9.4  	 CD	O
±  	±  	 CD	O
3.4  	3.4  	 CD	O
mmHg  	mmHg  	 NN	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
normal  	normal  	 JJ	B-NP
ECV  	ECV  	 NNP	I-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
P  	P  	 NNP	O
< 	< 	 SYM	O
0.01 	0.01 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
We  	We  	 PRP	O
did  	did  	 VBD	O
not  	not  	 RB	O
find  	find  	 VB	O
differences  	differences  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
decrease  	decrease  	 NN	O
in  	in  	 IN	O
diastolic  	diastolic  	 JJ	B-NP
BP  	BP  	 NNP	I-NP
between  	between  	 IN	O
the  	the  	 DT	O
groups 	groups 	 NNS	O
.  	.  	 .	O
Nine  	Nine  	 CD	O
patients  	patients  	 NNS	O
( 	( 	 -LRB-	O
30 	30 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
with  	with  	 IN	O
ECV  	ECV  	 NNP	B-NP
expansion  	expansion  	 NN	I-NP
who  	who  	 WP	O
increased  	increased  	 VBD	O
diuretic  	diuretic  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
reached  	reached  	 VBD	O
the  	the  	 DT	O
target  	target  	 NN	B-NP
blood  	blood  	 NN	I-NP
pressure  	pressure  	 NN	I-NP
( 	( 	 -LRB-	O
BP 	BP 	 NNP	B-NP
)  	)  	 -RRB-	O
of  	of  	 IN	O
< 	< 	 SYM	O
140 	140 	 CD	O
/ 	/ 	 CD	O
90  	90  	 CD	O
mmHg 	mmHg 	 NN	B-NP
,  	,  	 ,	O
when  	when  	 WRB	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
only  	only  	 RB	O
two  	two  	 CD	O
patients  	patients  	 NNS	O
( 	( 	 -LRB-	O
10 	10 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
who  	who  	 WP	O
had  	had  	 VBD	O
normal  	normal  	 JJ	B-NP
ECV  	ECV  	 NNP	I-NP
and  	and  	 CC	O
in  	in  	 IN	O
whom  	whom  	 WP	O
other  	other  	 JJ	O
antihypertensive  	antihypertensive  	 JJ	B-NP
drug  	drug  	 NN	I-NP
was  	was  	 VBD	O
added 	added 	 VBN	O
.  	.  	 .	O
A  	A  	 DT	O
total  	total  	 JJ	B-NP
decrease  	decrease  	 NN	I-NP
in  	in  	 IN	O
body  	body  	 NN	O
water  	water  	 NN	O
of  	of  	 IN	O
1.9  	1.9  	 CD	O
±  	±  	 CD	O
1.1  	1.1  	 CD	O
L  	L  	 NNP	O
was  	was  	 VBD	O
observed  	observed  	 VBN	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
ECV  	ECV  	 NNP	B-NP
expansion  	expansion  	 NN	I-NP
who  	who  	 WP	O
intensified  	intensified  	 VBD	O
diuretic  	diuretic  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
at  	at  	 IN	O
the  	the  	 DT	O
expense  	expense  	 NN	O
of  	of  	 IN	O
a  	a  	 DT	O
decline  	decline  	 NN	O
in  	in  	 IN	O
ECV  	ECV  	 NNP	B-NP
of  	of  	 IN	O
1.1  	1.1  	 CD	O
±  	±  	 CD	O
1  	1  	 CD	O
L.  	L.  	 NNP	B-NP
eGFR  	eGFR  	 NNP	I-NP
remained  	remained  	 VBD	O
stable  	stable  	 JJ	O
in  	in  	 IN	O
both  	both  	 DT	O
groups  	groups  	 NNS	O
( 	( 	 -LRB-	O
47.1  	47.1  	 FW	O
±  	±  	 FW	O
21.1  	21.1  	 FW	O
versus  	versus  	 FW	O
54.1  	54.1  	 FW	O
±  	±  	 FW	O
25.2  	25.2  	 FW	O
mL 	mL 	 FW	B-NP
/ 	/ 	 FW	I-NP
min 	min 	 FW	I-NP
/ 	/ 	 FW	O
1.73  	1.73  	 FW	O
m 	m 	 FW	B-NP
( 	( 	 -LRB-	I-NP
2 	2 	 LS	I-NP
) 	) 	 -RRB-	O
;  	;  	 :	O
P  	P  	 NN	O
=  	=  	 SYM	O
0.37 	0.37 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
An  	An  	 DT	O
increase  	increase  	 NN	O
in  	in  	 IN	O
ECV  	ECV  	 NNP	B-NP
as  	as  	 RB	O
measured  	measured  	 VBN	O
by  	by  	 IN	O
BIS  	BIS  	 NNP	B-NP
frequently  	frequently  	 RB	O
occurs  	occurs  	 VBZ	O
in  	in  	 IN	O
RHT  	RHT  	 NNP	B-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
CKD 	CKD 	 NNP	B-NP
.  	.  	 .	O
Diabetic  	Diabetic  	 NNP	O
and  	and  	 CC	O
severe  	severe  	 JJ	O
proteinuric  	proteinuric  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
are  	are  	 VBP	O
more  	more  	 RBR	O
exposed  	exposed  	 VBN	O
to  	to  	 TO	O
expansion  	expansion  	 NN	O
of  	of  	 IN	O
ECV 	ECV 	 NNP	B-NP
.  	.  	 .	O
BIS  	BIS  	 NNP	B-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
potentially  	potentially  	 RB	O
useful  	useful  	 JJ	O
method  	method  	 NN	O
for  	for  	 IN	O
identifying  	identifying  	 VBG	O
and  	and  	 CC	O
treating  	treating  	 VBG	B-NP
patients  	patients  	 NNS	I-NP
with  	with  	 IN	O
RHT  	RHT  	 NNP	B-NP
and  	and  	 CC	O
expansion  	expansion  	 NN	O
of  	of  	 IN	O
ECV 	ECV 	 NNP	B-NP
.  	.  	 .	O
The  	The  	 DT	O
hypothesis  	hypothesis  	 NN	O
generated  	generated  	 VBD	O
by  	by  	 IN	O
this  	this  	 DT	O
exploratory  	exploratory  	 JJ	B-NP
study  	study  	 NN	I-NP
needs  	needs  	 VBZ	O
to  	to  	 TO	O
be  	be  	 VB	O
tested  	tested  	 VBN	O
in  	in  	 IN	O
a  	a  	 DT	O
randomized  	randomized  	 JJ	B-NP
clinical  	clinical  	 JJ	I-NP
trial 	trial 	 NN	I-NP
.  	.  	 .	O
